An Italian startup has teamed with critical-care immunotherapy company CytoSorbents Corporation (NASDAQ: CTSO) on an integrated ex-vivo system to perfuse, cleanse, recondition and preserve harvested kidneys and livers — including those that are usually discarded.
Aferetica srl (Mirandola, Italy) designed its PerLife system is to improve organ function and viability while reducing the risk of primary graft failure and organ rejection. PerLife incorporates CytoSorbents’ PerSorb sorbent cartridge, which uses adsorptive porous polymer technology to reduce a broad range of toxins that can compromise organ function from the perfusate.
One major targeted use is the reconditioning of unusable or sub-optimally functioning “marginal” organs that are typically discarded. This may increase the availability of scarce, suitable organs and improve the clinical outcomes of complex and expensive transplantation procedures, according to a statement from both companies. Aferetica and CytoSorbents (Monmouth Junction, New Jersey) announced the system’s debut with a scientific presentation at the 27thInternational Congress of the Transplantation Society (TTS 2018) in Madrid, Spain last week.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!